ticlopidine has been researched along with Ischemic Stroke in 12 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Ischemic Stroke: Stroke due to BRAIN ISCHEMIA resulting in interruption or reduction of blood flow to a part of the brain. When obstruction is due to a BLOOD CLOT formed within in a cerebral blood vessel it is a thrombotic stroke. When obstruction is formed elsewhere and moved to block a cerebral blood vessel (see CEREBRAL EMBOLISM) it is referred to as embolic stroke. Wake-up stroke refers to ischemic stroke occurring during sleep while cryptogenic stroke refers to ischemic stroke of unknown origin.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile." | 8.12 | Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia. ( Harahap, AR; Harris, S; Herqutanto, H; Hidayat, R; Listyaningsih, E; Loho, T; Louisa, M; Nabilah, RA; Rambe, AS; Rasyid, A, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA)." | 5.22 | The role of ( Bath, PM; Leach, M; McDermott, JH; Newman, WG; Sen, D; Smith, CJ, 2022) |
| "Long-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for secondary stroke prevention in patients with noncardioembolic ischemic stroke." | 5.22 | Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies. ( Moustafa, B; Testai, FD, 2022) |
| "To compare the effectiveness of aspirin-clopidogrel dual antiplatelet therapy (DAPT) with aspirin or clopidogrel antiplatelet monotherapy (AM) in patients with ischemic stroke." | 4.31 | Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke. ( Algarni, RA; Alshargi, O; Alshehri, S; Alshibani, M; Althagafi, AA, 2023) |
| "Clopidogrel is a common antiplatelet used as secondary prevention of ischemic stroke, known to have better efficacy than aspirin, with a equivalent safety profile." | 4.12 | Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia. ( Harahap, AR; Harris, S; Herqutanto, H; Hidayat, R; Listyaningsih, E; Loho, T; Louisa, M; Nabilah, RA; Rambe, AS; Rasyid, A, 2022) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| "To investigate the relationship between plasma microRNA-223 expression and platelet reactivity in patients with acute ischemic stroke (AIS) and to evaluate its predictive value in clopidogrel resistance or high on-treatment platelet reactivity (HTPR)." | 4.12 | A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke. ( Li, X; Sun, Y; Tian, WJ; Wang, DL; Wang, L; Wang, RN; Xia, XS, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, Y | 1 |
| Zhao, J | 1 |
| Zhang, Y | 1 |
| Wu, L | 1 |
| Yu, Z | 1 |
| He, D | 1 |
| Huang, H | 1 |
| Qu, W | 1 |
| Luo, X | 1 |
| Zhang, S | 1 |
| Zhu, J | 1 |
| Li, H | 2 |
| Li, F | 1 |
| Zhu, B | 1 |
| Li, T | 1 |
| Fang, S | 1 |
| Qin, S | 1 |
| Lin, J | 1 |
| Mo, Y | 1 |
| Mao, D | 1 |
| Fu, H | 1 |
| Wei, D | 1 |
| Hidayat, R | 1 |
| Nabilah, RA | 1 |
| Rasyid, A | 1 |
| Harris, S | 1 |
| Harahap, AR | 1 |
| Herqutanto, H | 1 |
| Louisa, M | 1 |
| Listyaningsih, E | 1 |
| Rambe, AS | 1 |
| Loho, T | 1 |
| Wang, X | 1 |
| Zhu, Q | 1 |
| Wu, Y | 1 |
| Deng, X | 1 |
| Cheng, J | 1 |
| Zhang, Z | 1 |
| Ma, Y | 1 |
| Shi, T | 1 |
| Wang, DL | 1 |
| Li, X | 1 |
| Wang, RN | 1 |
| Sun, Y | 1 |
| Xia, XS | 1 |
| Tian, WJ | 1 |
| Wang, L | 1 |
| McDermott, JH | 1 |
| Leach, M | 1 |
| Sen, D | 1 |
| Smith, CJ | 1 |
| Newman, WG | 1 |
| Bath, PM | 1 |
| Moustafa, B | 1 |
| Testai, FD | 1 |
| Chang, R | 1 |
| Zhou, W | 1 |
| Ye, Y | 1 |
| Zhang, X | 1 |
| Liu, Y | 1 |
| Wu, J | 1 |
| Liu, H | 1 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Wang, H | 1 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 1 |
| Algarni, RA | 1 |
| Althagafi, AA | 1 |
| Alshehri, S | 1 |
| Alshibani, M | 1 |
| Alshargi, O | 1 |
| Song, TJ | 1 |
| Kim, J | 1 |
| Han, SW | 1 |
| Kim, YD | 1 |
| Lee, JY | 1 |
| Ahn, SH | 1 |
| Lee, HS | 1 |
| Jung, YH | 1 |
| Lee, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ticlopidine and Ischemic Stroke
| Article | Year |
|---|---|
The role of
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2022 |
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
10 other studies available for ticlopidine and Ischemic Stroke
| Article | Year |
|---|---|
Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients.
Topics: Brain Ischemia; Glucose; Humans; Ischemic Stroke; Platelet Aggregation; Platelet Aggregation Inhibit | 2021 |
Associations of CYP2C19 and F2R genetic polymorphisms with platelet reactivity in Chinese ischemic stroke patients receiving clopidogrel therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stroke; Platelet Aggregation Inhibi | 2022 |
CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
Topics: Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Sec | 2021 |
Clopidogrel Resistance Among Ischemic Stroke Patients and Its Risk Factors in Indonesia.
Topics: Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Indonesia; Ischemic Stroke; | 2022 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Ischemic Stro | 2022 |
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Topics: Aged; Aspirin; Cerebral Infarction; China; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; | 2022 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Comparative effectiveness of dual antiplatelet therapy versus monotherapy in patients with ischemic stroke.
Topics: Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Humans; Ischemic Stroke; P | 2023 |
Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.
Topics: Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Ischemic Stroke; Multicente | 2020 |